SHENGBANDA Biotechnology

Shengbanda Biotechnology is a Beijing-based biopharmaceutical company specializing in the development of next-generation mRNA and circular RNA (circRNA) therapeutics. Founded in 2021, the company leverages its proprietary platform to design stable, high-expression RNA molecules for vaccines and protein replacement therapies. Their pipeline primarily targets infectious diseases, including COVID-19, and various oncology indications through cytokine expression. Shengbanda aims to overcome the stability and immunogenicity limitations of traditional linear mRNA through its advanced circRNA engineering technology. The company has successfully raised significant venture capital to advance its preclinical programs toward clinical trials.